Loading clinical trials...
Loading clinical trials...
The Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury (PNI)
The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC) augmentation of nerve autograft repair in participants with severe peripheral nerve injury (PNI). For humans with acute severe PNI, the hypothesis is that augmentation of nerve autograft repair with ahSCs can potentially enhance axonal regeneration and myelin repair and thus improve functional recovery.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
University of Miami
Miami, Florida, United States
Start Date
September 24, 2019
Primary Completion Date
December 4, 2025
Completion Date
December 4, 2025
Last Updated
December 12, 2025
5
ACTUAL participants
autologous human Schwann cells
BIOLOGICAL
Lead Sponsor
W. Dalton Dietrich
Collaborators
NCT04789044
NCT07360730
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT01526681